iPS Cells for Modelling and Treatment of Retinal Diseases

Fred K Chen, Samuel McLenachan, Michael Edel, Lyndon Da Cruz, Peter J Coffey, David A Mackey

Research output: Contribution to journalReview articlepeer-review


For many decades, we have relied on immortalised retinal cell lines, histology of enucleated human eyes, animal models, clinical observation, genetic studies and human clinical trials to learn more about the pathogenesis of retinal diseases and explore treatment options. The recent availability of patient-specific induced pluripotent stem cells (iPSC) for deriving retinal lineages has added a powerful alternative tool for discovering new disease-causing mutations, studying genotype-phenotype relationships, performing therapeutics-toxicity screening and developing personalised cell therapy. This review article provides a clinical perspective on the current and potential benefits of iPSC for managing the most common blinding diseases of the eye: inherited retinal diseases and age-related macular degeneration.

Original languageEnglish
Pages (from-to)1511-1541
Number of pages31
JournalJournal of Clinical Medicine
Issue number4
Publication statusPublished - 19 Dec 2014


Dive into the research topics of 'iPS Cells for Modelling and Treatment of Retinal Diseases'. Together they form a unique fingerprint.

Cite this